This first became apparent in 2023 when the company shared the results from a phase 2 trial : study participants who ramped up to 12 mg (the highest dose) lost up to 24% of their body weight in a little less than a year
Whatever the category, the structure is the same: platform, independent licensed provider, licensed pharmacy, with prescription at provider discretion
Its super simple, as you can see
This is a flawed approach
The burning question is whether Hims customers are made aware, understand, and are willing to take on risks with an off-label product, even if it is delivered via slick marketing and a consumer-friendly interface
Yet as a frequent traveler reliant on takeout, weight loss was slow despite repeated dose increases